MK 2748

Drug Profile

MK 2748

Alternative Names: MK-2748

Latest Information Update: 12 Apr 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antivirals
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 27 Aug 2012 Merck & Co appears to discontinue recruitment in its phase I trial for Hepatitis C in Moldova, and begins recruiting in Lithuania (NCT01593735)
  • 31 May 2012 Phase-I clinical trials in Hepatitis C in Moldova (PO)
  • 31 May 2012 Phase-I clinical trials in Hepatitis C in Lithuania (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top